India Glycols

Why is India Glycols Ltd falling/rising?

As of 20-Jul, India Glycols Ltd's stock price is currently 1,143.10, down 1.55% after a trend reversal following seven days of gains. Despite this decline, the stock has shown strong long-term performance, with significant increases over the past month and three years, although it is currently underperforming its sector.

As of 20-Jul, India Glycols Ltd's stock price is falling, currently at 1,143.10, reflecting a decrease of 18.05 or 1.55%. This decline follows a trend reversal after seven consecutive days of gains. Despite the recent downturn, the stock has shown strong performance over various periods, including a 19.58% increase over the past month and a remarkable 277.98% rise over the last three years. <BR><BR>Today's performance indicates that the stock underperformed its sector by 3.67%, and the trading volume suggests that more transactions occurred closer to the low price, indicating potential selling pressure. Additionally, while the stock is trading above its moving averages, the recent drop may be attributed to profit-taking after a significant rally. <BR><BR>The company has consistently reported positive results over the last five quarters, with a return on capital employed (ROCE) at 11.79% and a low debt-equity ratio of 0.58, which supports a favorable valuation compared to peers. However, the immediate market reaction appears to be negative, as evidenced by the stock's current decline.

Which are the latest news on India Glycols?

How big is India Glycols?

As of 10th June, India Glycols Ltd has a market capitalization of 6,564.00 Cr, with recent net sales of 4,211.41 Cr and a net profit of 292.76 Cr.

As of 10th June, India Glycols Ltd has a market capitalization of 6,564.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, India Glycols reported Net Sales of 4,211.41 Cr and a Net Profit of 292.76 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,255.88 Cr and Total Assets of 6,176.10 Cr.

Who are in the management team of India Glycols?

The management team of India Glycols includes U S Bhartia (Chairman/Executive Director), Pragya Bhartia Barwale, Sudhir Agarwal (both Executive Directors), and several Independent Non-Executive Directors, including Pradip Kumar Khaitan and Jitender Balakrishnan. This diverse team provides strong leadership and expertise to the company.

The management team of India Glycols includes the following key members:<BR><BR>1. **U S Bhartia** - Chairman / Executive Director<BR>2. **Jayshree Bhartia** - Non-Executive Director<BR>3. **Pragya Bhartia Barwale** - Executive Director<BR>4. **Sudhir Agarwal** - Executive Director<BR>5. **Pradip Kumar Khaitan** - Independent Non-Executive Director<BR>6. **Jitender Balakrishnan** - Independent Non-Executive Director<BR>7. **Ravi Jhunjhunwala** - Independent Non-Executive Director<BR>8. **Jagmohan N Kejriwal** - Independent Non-Executive Director<BR>9. **Sajeve Deora** - Independent Non-Executive Director<BR>10. **Shukla Wassan** - Independent Non-Executive Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the India Glycols?

Peers of India Glycols include Tata Chemicals, Gujarat Alkalies, GHCL, Tanfac Inds., Chemplast Sanmar, and others. In terms of performance, Tanfac Inds. leads with a 1-year return of 20.11%, while India Glycols has a return of 4.70%.

Peers: The peers of India Glycols are Tata Chemicals, Gujarat Alkalies, GHCL, Tanfac Inds., Grauer & Weil, Chemplast Sanmar, Fischer Medical, Thirumalai Chem., and J.G.Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tata Chemicals, India Glycols, Gujarat Alkalies, Tanfac Inds., Grauer & Weil, Thirumalai Chem., and J.G.Chemicals, and the rest. Good management risk is noted at Fischer Medical. For Growth, Excellent growth is seen at Fischer Medical, while Good growth is noted at Tanfac Inds. and J.G.Chemicals, and the rest show Below Average growth. In terms of Capital Structure, Excellent capital structure is observed at Gujarat Alkalies, GHCL, Tanfac Inds., Grauer & Weil, and J.G.Chemicals, while Average capital structure is found at Tata Chemicals and India Glycols, and Below Average at Chemplast Sanmar, Fischer Medical, Thirumalai Chem.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Tanfac Inds. at 20.11%, while the lowest is Fischer Medical at -61.28%. India Glycols has a 1-year return of 4.70%, which is higher than Fischer Medical but lower than Tanfac Inds. Additionally, GHCL, Chemplast Sanmar, Fischer Medical, Thirumalai Chem., and Grauer & Weil all have negative six-month returns.

What does India Glycols do?

India Glycols Ltd is a small-cap company in the commodity chemicals industry, producing products for textiles, agrochemicals, and pharmaceuticals. As of March 2026, it reported net sales of ₹976 Cr and a net profit of ₹87 Cr, with a market cap of ₹6,564 Cr.

Overview: <BR>India Glycols Ltd operates in the commodity chemicals industry, providing a range of products to various sectors including textiles, agrochemicals, and pharmaceuticals, and is classified as a small-cap company.<BR><BR>History: <BR>India Glycols Limited was incorporated as UP Glycols Limited and changed its name in September 1986. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 976 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 87 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 6,564 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 1.24% <BR>Debt-Equity: 0.56 <BR>Return on Equity: 10.00% <BR>Price to Book: 2.24<BR><BR>Contact Details: <BR>Address: A-1 Industrial Area, Bazpur Road Kashipur Udham Singh Nagar UTT : 244713 <BR>Tel: 91-05947-269000/269500/275320 <BR>Email: compliance.officer@indiaglycols.com <BR>Website: http://www.indiaglycols.com

Should I buy, sell or hold India Glycols Ltd?

Are India Glycols Ltd latest results good or bad?

India Glycols Ltd's latest Q4 FY26 results show strong profitability with a net profit increase of 28.58% quarter-on-quarter, but a concerning 11.43% decline in net sales compared to the previous quarter. Overall, the results are good in terms of profit but mixed due to the revenue drop.

India Glycols Ltd's latest results for Q4 FY26 present a mixed picture. On one hand, the company achieved a consolidated net profit of ₹86.88 crores, marking a significant 28.58% increase quarter-on-quarter and a remarkable 35.71% growth year-on-year. This reflects strong profitability momentum and operational efficiency.<BR><BR>However, net sales decreased by 11.43% compared to the previous quarter, totaling ₹976.35 crores, although there was a year-on-year increase of 13.11%. This sequential decline in revenue raises some concerns about demand sustainability, especially given the typical seasonal patterns in the chemicals industry.<BR><BR>The operating margin also showed positive signs, reaching 17.05%, which is the highest in several quarters, indicating effective cost management and a focus on higher-margin products. The profit after tax (PAT) margin improved to 8.90%, further underscoring the company's ability to enhance profitability despite revenue pressures.<BR><BR>In summary, while the profit figures are strong and indicate effective operational management, the decline in sales could be a point of concern. Overall, the results can be seen as good in terms of profitability but mixed due to the revenue drop.

When is the next results date for India Glycols Ltd?

The next results date for India Glycols Ltd is 14 May 2026.

The next results date for India Glycols Ltd is scheduled for 14 May 2026.

Has India Glycols Ltd declared dividend?

Yes, India Glycols Ltd has declared a dividend of 150%, amounting to ₹5 per share, with an ex-date of March 23, 2026. The company has demonstrated strong total returns across various periods, with a notable 306.65% total return over the last 5 years.

India Glycols Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 5<BR>- Ex-date: 23 Mar 26<BR><BR>Dividend Yield: 0.54%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -15.73%, the dividend return was 0.72%, resulting in a total return of -15.01%.<BR><BR>Over the past 6 months, the price return was 3.69%, the dividend return was 1.43%, leading to a total return of 5.12%.<BR><BR>In the 1-year period, the price return was 57.02%, with a dividend return of 2.29%, culminating in a total return of 59.31%.<BR><BR>For the 2-year period, the price return was 123.49%, the dividend return was 5.42%, resulting in a total return of 128.91%.<BR><BR>In the last 3 years, the price return was 200.09%, with a dividend return of 9.19%, leading to a total return of 209.28%.<BR><BR>Over the past 4 years, the price return was 99.42%, the dividend return was 6.71%, resulting in a total return of 106.13%.<BR><BR>In the 5-year period, the price return was 287.34%, with a dividend return of 19.31%, culminating in a total return of 306.65%.<BR><BR>Overall, India Glycols Ltd has declared a significant dividend and has shown strong total returns over various periods, indicating a positive performance trend for the company.

How has been the historical performance of India Glycols?

India Glycols has shown significant growth in net sales and profits, with net sales increasing from 2,316.99 Cr in Mar'21 to 3,768.26 Cr in Mar'25, and profit after tax rising from 129.67 Cr to 184.52 Cr in the same period, despite rising raw material costs. The company's operating profit margin improved to 13.56% in Mar'25, reflecting its strong financial performance.

Answer:<BR>The historical performance of India Glycols shows a significant upward trend in net sales and profit over the years, with the latest figures indicating a robust growth trajectory.<BR><BR>Breakdown:<BR>India Glycols has demonstrated a consistent increase in net sales, rising from 2,316.99 Cr in Mar'21 to 3,768.26 Cr in Mar'25. This growth is accompanied by a rise in total operating income, which reached 3,768.26 Cr in Mar'25, up from 2,650.86 Cr in Mar'23. The company's operating profit (PBDIT) also improved, reaching 525.49 Cr in Mar'25, compared to 319.42 Cr in Mar'23. Profit before tax increased to 245.92 Cr in Mar'25 from 153.63 Cr in Mar'23, while profit after tax rose to 184.52 Cr from 129.67 Cr in the same period. Despite fluctuations in expenses, including a notable increase in raw material costs, the operating profit margin improved to 13.56% in Mar'25 from 11.15% in Mar'23. The total assets of the company grew to 6,176.10 Cr in Mar'25, up from 4,858.33 Cr in Mar'23, while total liabilities also increased to 6,176.10 Cr from 4,858.33 Cr. Cash flow from operating activities was strong at 362.00 Cr in Mar'25, although the company faced a net cash outflow of 20.00 Cr. Overall, India Glycols has shown resilience and growth in its financial performance over the years.

Is India Glycols technically bullish or bearish?

As of 9 October 2025, the trend has shifted to bullish with moderate strength, supported by bullish daily moving averages and positive Bollinger Bands, although caution is advised due to mildly bearish weekly MACD and KST indicators.

As of 9 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators supporting this include the daily moving averages being bullish and both the weekly and monthly Bollinger Bands indicating bullish momentum. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The overall performance metrics show strong returns compared to the Sensex, particularly over longer time frames, reinforcing the bullish outlook.

Is India Glycols overvalued or undervalued?

As of August 8, 2025, India Glycols is considered overvalued with a PE ratio of 22.10, despite outperforming the Sensex with a 34.57% year-to-date return, as it has moved from a fair to an expensive valuation grade compared to its peers.

As of 8 August 2025, India Glycols has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its key financial ratios. The PE ratio stands at 22.10, while the Price to Book Value is 2.39, and the EV to EBITDA is 13.46. These ratios indicate a premium valuation compared to its peers.<BR><BR>In comparison to its industry peers, India Glycols' PE ratio is significantly lower than Solar Industries at 103.57 and Gujarat Fluoroch at 61.32, both categorized as very expensive. However, it is higher than Godrej Industries, which is rated attractive with a PE of 37.72. The company's recent stock performance has outpaced the Sensex, with a year-to-date return of 34.57% compared to the Sensex's 2.20%, but this does not alter the overall assessment of its current valuation.

Who are the top shareholders of the India Glycols?

The top shareholder of India Glycols is Kashipur Holdings Limited, owning 50.35%. Other notable shareholders include 50 Foreign Institutional Investors with 2.25%, mutual funds with 0.12%, and individual investors holding 28.68%, with Puneet Bhatia as the largest public shareholder at 1.92%.

The top shareholders of India Glycols include Kashipur Holdings Limited, which holds the largest share at 50.35%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, there are 50 Foreign Institutional Investors (FIIs) collectively holding 2.25% of the shares, and mutual funds are represented by 8 schemes with a total holding of 0.12%. The highest public shareholder is Puneet Bhatia, who owns 1.92%. Individual investors collectively hold 28.68% of the company's shares.